(Q37981224)

26 August 2017

title

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

26 August 2017

main subject

0 references

author name string

John A Morren

series ordinal

1

1 reference

26 August 2017

Nestor Galvez-Jimenez

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

6 February 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

297-320

1 reference

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Neuroprotective agents for clinical trials in ALS: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Molecular chaperones in cellular protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Genetic variant in the HSPB1 promoter region impairs the HSP27 stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Antisense oligonucleotide therapy for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Autophagy, lithium, and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Degradation of Amyotrophic Lateral Sclerosis-linked Mutant Cu,Zn-Superoxide Dismutase Proteins by Macroautophagy and the Proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Lithium delays progression of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Autophagy in metazoans: cell survival in the land of plenty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Small molecule enhancers of autophagy for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Small molecule regulators of autophagy identified by an image-based high-throughput screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

APP binds DR6 to trigger axon pruning and neuron death via distinct caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Reduced oxidative damage in ALS by high-dose enteral melatonin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Coenzyme Q10 as a possible treatment for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Manganese porphyrin given at symptom onset markedly extends survival of ALS mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Clinical trials for neuroprotection in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Expression and localization of cyclooxygenase‐1 and ‐2 in human sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

T cells in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Inflammation in ALS and SMA: sorting out the good from the evil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Experimental rationale for the therapeutic use of neurotrophins in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A prospective, randomized, placebo‐controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

IGF-I prevents glutamate-induced motor neuron programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Insulin-like growth factor-I and central nervous system development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Functional motoneurons develop from human neural stem cell transplants in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Cellular transplants in amyotrophic lateral sclerosis patients: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

In vitro and in vivo characterization of tapentadol metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Extracellular regulators of axonal growth in the adult central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Electrical impedance myography as a biomarker for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Audit of outcomes in motor neuron disease (MND) patients treated with riluzole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

Amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.657303

10.1517/13543784.2012.657303

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference